Driving Medical Innovation: SBC's Vision for Accelerated Growth and AI-Powered Healthcare
Robust Financial Performance in the Second Quarter of 2026
For the second quarter of 2026, SBC Medical Group Holdings Inc. achieved a total revenue of $49 million, marking a 13% year-over-year increase. Net income attributable to SBC Medical surged by 335% to $11 million, largely due to the successful completion of structural reforms. Adjusted EBITDA reached $20 million, a 32% rise, reflecting improved operational efficiency, while the adjusted EBITDA margin expanded to 41%, overcoming currency headwinds from a weaker yen. Basic EPS saw a 400% increase, reaching $0.10 compared to $0.02 in the prior-year period.
Strategic Expansion of Clinic Network and Customer Engagement
As of June 30, 2026, the company's network encompassed 287 clinic locations, an addition of 34 sites over the year. Customer visits climbed by 10% year-over-year, totaling 6.92 million over the trailing twelve months. The average spend per visit increased by 9% to $287, indicating higher utilization of advanced medical treatments. Same-clinic revenue also grew by 6%, fueled by an uptick in both customer volume and pricing. Gorilla Clinic's transaction value for the first half of the year reached $62 million, up 19%, driven by deeper engagement with existing clientele.
Addressing Market Challenges and Leveraging Growth Opportunities
Despite a competitive landscape in Japanese aesthetic medicine, especially fierce in 2024 and 2025, SBC Medical has successfully reaccelerated its growth. CEO Yoshiyuki Aikawa emphasized the company's strategic review of marketing methods, fee structures, and treatment offerings, leading to renewed strength. The appointment of a Chief Marketing Officer and a comprehensive overhaul of social media and advertising strategies have contributed significantly to these positive outcomes. CFO Yuya Yoshida noted that the company's growth is now outpacing market expansion, reinforcing SBC's leading position.
Innovation Through AI and Cost Efficiency
SBC is increasingly leveraging AI to enhance both growth and efficiency. By analyzing over 26 years of management data, the company is developing AI-powered solutions that serve as a competitive advantage. AI chatbots and interpreters are already deployed, with a call center AI and marketing AI being rolled out to improve customer experience and operational effectiveness. These initiatives aim to maintain indirect department headcount while expanding to 1,000 clinics by 2035, significantly improving margins.
Global Outreach and Investment in Longevity Services
The company's global expansion includes advanced collaborations with OrangeTwist in the United States, where SBC is sharing operational expertise and expanding service menus. In Southeast Asia, SBC is implementing an asset-light operating model, providing procurement, standardization, training, and patient acquisition support to local partners, starting with BLEZ CLINIC in Thailand. Additionally, SBC is strategically investing in the longevity market, aiming to become synonymous with healthy aging in Japan through regenerative medicine, gene screening, and an upcoming longevity center and online platform in 2027.
Financial Strength and Shareholder Value Enhancement
With $184 million in cash and cash equivalents, SBC is poised for disciplined investments in organic growth and strategic acquisitions. The company's shareholder base has grown significantly, reflecting increased capital market recognition. SBC plans to continue active participation in IR conferences and investor engagement to enhance shareholder value over the medium to long term, ensuring continuous EPS growth and appropriate valuation.
Future Outlook and Concluding Remarks
SBC Medical Group Holdings Inc. is confident in its strategic direction, anticipating continued robust growth across its diversified medical services. The successful integration of AI, coupled with a proactive global expansion and a strong focus on longevity-driven healthcare, positions SBC to achieve its ambitious goal of 1,000 clinics by 2035. The company remains dedicated to delivering enhanced value to its shareholders and stakeholders.
